These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25278593)

  • 21. Pharmacogenomics update in pancreatic cancer.
    Puri A; Saif MW
    JOP; 2014 Mar; 15(2):114-7. PubMed ID: 24618431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective suppression of the Kirsten rat sarcoma viral oncogene in pancreatic tumor cells via targeted small interfering RNA delivery using nanoparticles.
    Zeng L; Li J; Li J; Zhang Q; Qian C; Wu W; Lin Z; Liang J; Chen Y; Huang K
    Pancreas; 2015 Mar; 44(2):250-9. PubMed ID: 25401377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EUS-guided pancreatic fluid aspiration for DNA analysis of KRAS and GNAS mutations for the evaluation of pancreatic cystic neoplasia: a pilot study.
    Siddiqui AA; Kowalski TE; Kedika R; Roy A; Loren DE; Ellsworth E; Adler D; Finkelstein SD
    Gastrointest Endosc; 2013 Apr; 77(4):669-70. PubMed ID: 23498145
    [No Abstract]   [Full Text] [Related]  

  • 24. K-ras mutations in circulating DNA from pancreatic and lung cancers: bridging methodology for a common validation of the molecular diagnosis value.
    Magistrelli P; Neri M; Granone P; Cesario A; Paleari L; Russo P
    Pancreas; 2008 Jul; 37(1):101-2. PubMed ID: 18580451
    [No Abstract]   [Full Text] [Related]  

  • 25. Detection of point mutations of K-ras oncogene and p53 tumor-suppressor gene in sputum samples.
    Gao W; Keohavong P
    Methods Mol Biol; 2014; 1105():325-44. PubMed ID: 24623240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
    Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
    Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pancreatic adenocarcinoma.
    Ryan DP; Hong TS; Bardeesy N
    N Engl J Med; 2014 Sep; 371(11):1039-49. PubMed ID: 25207767
    [No Abstract]   [Full Text] [Related]  

  • 28. K-ras mutations in the plasma correspond to computed tomographic findings in patients with pancreatic cancer.
    Däbritz J; Preston R; Hänfler J; Oettle H
    Pancreas; 2012 Mar; 41(2):323-5. PubMed ID: 22044911
    [No Abstract]   [Full Text] [Related]  

  • 29. Shining the spotlight on shed KRAS in pancreatic cancer.
    Sempere LF; Korc M
    Cancer Biol Ther; 2008 Mar; 7(3):361-3. PubMed ID: 18614859
    [No Abstract]   [Full Text] [Related]  

  • 30. Intraductal tubular carcinoma of the pancreas: case report with molecular analysis.
    Furukawa T; Hatori T; Fukuda A; Fujita I; Yamamoto M
    Pancreas; 2009 Mar; 38(2):235-7. PubMed ID: 19238030
    [No Abstract]   [Full Text] [Related]  

  • 31. The impact of TP53 and RAS mutations on cerebellar glioblastomas.
    Milinkovic VP; Skender Gazibara MK; Manojlovic Gacic EM; Gazibara TM; Tanic NT
    Exp Mol Pathol; 2014 Oct; 97(2):202-7. PubMed ID: 25036404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A rapid procedure to evaluate foreign DNA transfer into mammals.
    Pinkert CA
    Biotechniques; 1990 Jul; 9(1):38-9. PubMed ID: 2203385
    [No Abstract]   [Full Text] [Related]  

  • 33. Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.
    Weyandt JD; Lampson BL; Tang S; Mastrodomenico M; Cardona DM; Counter CM
    PLoS One; 2015; 10(10):e0140253. PubMed ID: 26452271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations.
    Bleau AM; Freire J; Pajares MJ; Zudaire I; Anton I; Nistal-Villán E; Redrado M; Zandueta CN; Garmendia I; Ajona D; Blanco D; Pio R; Lecanda F; Calvo A; Montuenga LM
    Int J Cancer; 2014 Dec; 135(11):2516-27. PubMed ID: 24473991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
    Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer.
    Yu S; Lu Z; Liu C; Meng Y; Ma Y; Zhao W; Liu J; Yu J; Chen J
    Cancer Res; 2010 Jul; 70(14):6015-25. PubMed ID: 20610624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pancreatic ductal adenocarcinoma in hereditary diffuse gastric cancer. A case report.
    Ottenhof NA; de Wilde RF; Morsink FH; de Leng WW; Ausems MG; Morreau H; van Hillegersberg R; Offerhaus GJ; Milne AN
    Hum Pathol; 2012 Mar; 43(3):457-61. PubMed ID: 21992816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of p16 and K-ras mutation in pancreatic adenocarcinoma and chronic pancreatitis differential diagnosis.
    Talar-Wojnarowska R; Gasiorowska A; Smolarz B; Romanowicz-Makowska H; Strzelczyk J; Janiak A; Kulig A; Malecka-Panas E
    J Physiol Pharmacol; 2004 Jul; 55 Suppl 2():129-38. PubMed ID: 15608367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant therapy of pancreatic cancer.
    Chaulagain CP; Ng J; Wazer D; Saif MW
    JOP; 2012 Jul; 13(4):349-53. PubMed ID: 22797387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developing gene expression signatures of pathway deregulation in tumors.
    Watters JW; Roberts CJ
    Mol Cancer Ther; 2006 Oct; 5(10):2444-9. PubMed ID: 17041087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.